Edition:
United States

McKesson Corp (MCK.N)

MCK.N on New York Stock Exchange

161.42USD
3:30pm EDT
Change (% chg)

$-0.94 (-0.58%)
Prev Close
$162.36
Open
$161.83
Day's High
$162.90
Day's Low
$161.19
Volume
110,934
Avg. Vol
422,338
52-wk High
$199.22
52-wk Low
$114.54

Select another date:

Wed, May 24 2017

BRIEF-McKesson sets regular quarterly dividend of $0.28/share

* Sets regular quarterly dividend of $0.28/share Source text for Eikon: Further company coverage:

Drug distributor McKesson's upbeat forecast sends shares soaring

McKesson Corp reported a higher-than-expected quarterly profit and forecast an upbeat full-year earnings, easing concerns about the drug wholesaler's struggles with moderating branded drug price increases and falling prices for generics.

UPDATE 2-Drug distributor McKesson's upbeat forecast sends shares soaring

May 18 McKesson Corp reported a higher-than-expected quarterly profit and forecast an upbeat full-year earnings, easing concerns about the drug wholesaler's struggles with moderating branded drug price increases and falling prices for generics.

Drug distributor McKesson's quarterly revenue rises 4.4 pct

May 18 Drug wholesaler McKesson Corp reported a 4.4 percent rise in quarterly revenue, helped by strength in its pharmaceutical distribution and services business.

BRIEF-Mckesson anticipates recording pre-tax gain of about $2.9 to $3.5 bln in Q4

* As a result of net gain from transaction, co to add about $10.70-$12.35 in Q4 GAAP earnings per share from continuing operations

Fitch Rates McKesson's EUR and GBP Notes 'BBB+'; Outlook Stable

(The following statement was released by the rating agency) NEW YORK, February 13 (Fitch) Fitch Ratings has assigned 'BBB+' ratings to the EUR and GBP denominated senior unsecured notes issued by McKesson Corp. (NYSE: MCK). A full list of ratings follows at the end of the release. KEY RATING DRIVERS Stable Operations, Low Margins The credit profiles of MCK and its peers benefit from stable operating profiles and consistent cash generation. Steady pharmaceutical demand, an oligopolistic drug

BRIEF-Mckesson announces purchase of CoverMyMeds

* McKesson announces purchase of CoverMyMeds, a Francisco Partners portfolio company

McKesson's revenue misses as pace of drug price hikes slow

Drug distributor McKesson Corp's quarterly revenue missed estimates due to slowing pace of branded drug price increases amid rising concerns over soaring prices of medicines.

UPDATE 2-McKesson's revenue misses as pace of drug price hikes slow

Jan 25 Drug distributor McKesson Corp's quarterly revenue missed estimates due to slowing pace of branded drug price increases amid rising concerns over soaring prices of medicines.

BRIEF-McKesson to acquire CoverMyMeds for about $1.1 bln

* Q3 gaap earnings per share $2.86 from continuing operations

Select another date:

More From Around the Web